Related Experiment Video
Updated: May 23, 2026
11:31
Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
Published on: September 18, 2013
LRRK2 I2020T mutation is associated with tau pathology
Sachiko Ujiie1, Taku Hatano, Shin-Ichiro Kubo
1Department of Neurology, Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Parkinsonism & Related Disorders
|April 25, 2012
Summary
Mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial Parkinson's disease. This study reveals LRRK2 I2020T mutations enhance tau phosphorylation, linking LRRK2 to neurodegeneration pathways.
Area of Science:
- Neuroscience
- Genetics
- Pathology
Background:
- Leucine-rich repeat kinase 2 (LRRK2) mutations are a primary cause of autosomal-dominant familial Parkinson's disease (FPD).
- LRRK2-linked FPD pathology includes Lewy bodies, axonal spheroids, neurofibrillary tangles (NFTs), and TDP-43 inclusions.
- Abnormal tau hyperphosphorylation is implicated in neurodegeneration across various diseases, including FPD.
Purpose of the Study:
- To investigate the association between the LRRK2 I2020T mutation and tau pathology in familial Parkinson's disease.
- To explore the mechanistic link between LRRK2 I2020T and tau hyperphosphorylation.
Main Methods:
- Examination of brainstem tissue from six patients with the LRRK2 I2020T mutation.
- In vitro experiments co-expressing LRRK2 I2020T with 3 or 4-repeat tau in cultured cells.
Main Results:
- Abnormal tau phosphorylation depositions were identified in the brainstem of patients with the LRRK2 I2020T mutation.
- LRRK2 I2020T was found to enhance tau phosphorylation in co-expression cell cultures.
Conclusions:
- This study provides the first evidence of a direct relationship between LRRK2 I2020T mutation and enhanced tau hyperphosphorylation.
- These findings suggest a novel pathway involving LRRK2 in the pathogenesis of Parkinson's disease through tau modification.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
03:18Non-LTR Retrotransposons
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...